MedTrace Logo

Limb-Girdle Muscular Dystrophy Type 2I in Norway

NCT03930628 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2022-11-07

No results posted yet for this study

Summary

Key goals are to establish the natural history of limb-girdle muscular dystrophy type 2I (LGMD 2I) and identify feasible and sensitive tools and biomarkers to measure disease affection and progression, determine the Norwegian LGMD 2I prevalence, carrier frequency and genotypes, and to assess health-related quality of life in the Norwegian LGMD 2I population.

Main aims are to facilitate future clinical trials and contribute to good clinical practice with suitable methodology and to complete health and social care in order to optimize the function and quality of daily living of the patient group.

Conditions

  • Limb Girdle Muscular Dystrophy, Type 2I
  • Limb Girdle Muscular Dystrophy
  • Muscular Dystrophies
  • Limb Girdle Muscular Dystrophy R9 FKRP-related

Sponsors & Collaborators

  • University of Tromso

    collaborator OTHER

  • Norwegian Muscle Disease Association (FFM)

    collaborator UNKNOWN

  • Norwegian National Advisory Unit on Rare Disorders (NKSD)

    collaborator UNKNOWN

  • Norwegian Competence Center for Sleep Disorders

    collaborator UNKNOWN

  • University Hospital of North Norway

    lead OTHER

Principal Investigators

  • Kjell Arne Arntzen, ph.d · University Hospital of North Norway

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-06
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03930628 on ClinicalTrials.gov